Oxford University COVID-19 vaccine now 70% effective, Egypt reserves large share

Henrietta Brewer
November 23, 2020

Earlier, media reported preliminary results of clinical trials of the coronavirus vaccine being developed by the University of Oxford and the AstraZeneca pharmaceutical company claiming it has shown a sustainable immune reaction to infection among elderly people.

The lab explained that the results are temporary for clinical trials conducted on a large scale in Britain and Brazil.

He said that the results of the trials were "exciting" and demonstrated that they had an "effective vaccine that will save many lives".

It is not yet clear why the two dosages produced such different results.

"This vaccine's efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency, " AstraZeneca CEO Pascal Soriot said.

The Pfizer and BioNTech vaccine announced last week, and the Moderna vaccine announced earlier in the month, reportedly have efficacy rates exceeding 90 percent.

This story will be updated.

Second, the Oxford vaccine can be stored and transported at standard refrigerator temperatures - between 35° and 45°F - whereas the other two vaccine candidates require storage at lower temperatures.

Another week and more good news in the fight against COVID-19.

The Oxford University candidate is an adenovirus vaccine, which is a much more established technology that's already been in use for decades, and which involves genetically altering a weekend common cold virus and using that to trigger a person's own natural immune response.

On Monday, AstraZeneca's operations chief executive Pam Cheng said 20 million doses would be available in the United Kingdom by the end of the year, with an extra 70 million more available there by the end of March.

The 70% average is lower compared with the efficacy of coronavirus vaccines trialed by rivals Pfizer/BioNTech and Moderna which have come in above 90%. "It has been a privilege to be part of this multinational effort, which will reap benefits for the whole world", she added.

But according to the vaccine trial, their design required them to include all vaccination groups in their results - which acted to bring their apparent efficacy result down.

Scientists expressed optimism about today's announcement, while U.K. Health Secretary Matt Hancock told Sky News that the U.K. has "100 million doses on order and should all that go well, the bulk of the rollout will be in the new year". It could affect, for example, the possible extradition of two Americans, Michael Taylor and his son Peter, whom Japanese prosecutors say helped the executive sneak out of Japan.Ghosn, a 66-year-old with French, Lebanese and Brazilian citizenship, led Japanese automaker Nissan for two decades, rescuing it from near-bankruptcy.

Other reports by iNewsToday